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N
anostructures are of great impor-
tance for a wide variety of applica-
tions in cancer theranostics includ-
ing imaging, drug delivery, and therapy.1
Among various types of nanostructures,
those based on Au have received increasing
attention in recent years owing to their
tunable localized surfaceplasmon resonance
(LSPR) properties. Arising from the collective
oscillation of conduction electrons conﬁned
to a nanoscale structure, the LSPR causes
strong absorption and scattering of light
at tunable wavelengths for optical imaging
and photothermal destruction of tumors.24
By forming anisotropic shapes such as
nanorods, nanodisks, and nanocages, the
LSPR can be tuned into the transparent
window (700900 nm) of soft tissues in
the near-infrared (NIR) region to meet the
requirements for in vivo application.5 In
addition, Au nanostructures can be functio-
nalized with radioactive species for positron
emission tomography (PET) imaging,6 Cer-
enkov imaging,79 and/or radiotherapy10
through radiolabeling with βþ-emitting 64Cu
nuclides6 or incorporation of β-emitting
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ABSTRACT With Au nanocages as an example, we recently
demonstrated that radioactive 198Au could be incorporated into the
crystal lattice of Au nanostructures for simple and reliable quantiﬁca-
tion of their in vivo biodistribution by measuring the γ radiation from
198Au decay and for optical imaging by detecting the Cerenkov
radiation. Here we extend the capability of this strategy to synthesize
radioactive 198Au nanostructures with a similar size but diﬀerent shapes
and then compare their biodistribution, tumor uptake, and intratu-
moral distribution using a murine EMT6 breast cancer model. Speciﬁ-
cally, we investigated Au nanospheres, nanodisks, nanorods, and cubic nanocages. After PEGylation, an aqueous suspension of the radioactive Au
nanostructures was injected into a tumor-bearing mouse intravenously, and their biodistribution was measured from the γ radiation while their tumor
uptake was directly imaged using the Cerenkov radiation. Signiﬁcantly higher tumor uptake was observed for the Au nanospheres and nanodisks relative to
the Au nanorods and nanocages at 24 h postinjection. Furthermore, autoradiographic imaging was performed on thin slices of the tumor after excision to
resolve the intratumoral distributions of the nanostructures. While both the Au nanospheres and nanodisks were only observed on the surfaces of the
tumors, the Au nanorods and nanocages were distributed throughout the tumors.
KEYWORDS: Cerenkov imaging . radioactive gold nanostructures . biodistribution . tumor uptake . intratumoral distribution .
shape dependence
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198Au isotopes.11 Importantly, these radioactive ima-
ging modalities, whether based on γ-rays or visible
light, can be used not only for the in vivo bio-
distribution analysis of Au nanostructures but also for
monitoring their uptake by the targeted disease site.
To fully realize their potential in cancer theranostics,
the nanostructuresmust be able to enter the tumor and
be evenly distributed throughout the tumor, which is
composed of heterogeneous microenvironments con-
taining both vascular and avascular volumes.12 It has
been established that nanostructures can enter a tumor
by leaking out through the gaps between endothelial
cells of the chaotic andhyperpermeable vasculature of a
tumor through a mechanism known as the enhanced
permeability and retention (EPR) eﬀect.1316 The eﬃ-
cacy of this process depends on the physicochemical
characteristics of thenanostructures, includingboth size
and shape. It has been shown that spherical particles
of 50100 nm in diameter tend to present an op-
timal range of size for maximizing tumor accu-
mulation due to the EPR eﬀect and minimizing the
subsequent clearance.1719 Compared to nanospheres,
nanostructures with other shapes (e.g., nanorods) can
have distinct EPR eﬀects due to alterations to their
in vivo hydrodynamic behaviors such as circulation,
transport in blood ﬂow, and extravasation into the
tumor.2025 However, due to the diﬃculty in generat-
ing nanostructures with the same uniform size but
diﬀerent shapes from the same material, the eﬀect of
shape on the EPR eﬀect and thus tumor uptake still
needs further assessment. In addition, the inﬂuence of
size or shape of nanostructures on their in vivo intra-
tumoral distribution is yet to be explored despite its
paramount importance in cancer diagnosis and ther-
apy. While it has been observed that rod-shaped
nanostructures like carbon nanotubes tended to pene-
trate into the core of a tumor more eﬀectively com-
pared to their spherical counterparts like quantum
dots,26,27 there is essentially no study on the intratu-
moral distribution of nanostructures with similar sizes
but diﬀerent shapes, particularly those composed of
Au with interesting LSPR properties.
Due to the great potential of Au nanostructures for
oncological imaging and therapy, it is of great impor-
tance to systematically evaluate the eﬀects of their
shapes on biodistribution, tumor uptake, and intratu-
moral distribution. In this work, we accomplished these
goals in a murine EMT6 breast cancer model by
incorporating radioactive 198Au (β = 0.96 MeV, t1/2 =
2.7 days) into Au nanostructures with a similar size but
four diﬀerent shapes, including nanospheres, nano-
disks, nanorods, and cubic nanocages. The radioactive
198Au was directly incorporated into their crystal lat-
tices during the syntheses with precisely controlled
speciﬁc radioactivity. The characteristic γ emission
from 198Au was directly employed for a quantitative
analysis of the biodistribution in a tumor-bearing
mouse, whereas the Cerenkov luminescence derived
from the β emission was used for monitoring tumor
uptake in vivo and autoradiography imaging of intra-
tumoral distribution ex vivo. We also performed photo-
acoustic (PA) imaging, PET imaging, and hematoxylin
and eosin (H&E) histological staining to characterize
tumor vascularity, hypoxia, metabolism, and spatial
heterogeneity, respectively. Combined together, it
can be concluded that incorporation of 198Au into Au
nanostructures oﬀers a new platform to stably label
nanostructures for quantitative measurements of bio-
distribution, tumor uptake, and intratumoral distribu-
tion. The data collected from suchmultimodal imaging
demonstrated that the shape of Au nanostructures
indeed played a critical role in determining their
biodistribution, tumor uptake, and intratumoral distri-
bution in a murine EMT6 breast cancer model, which
can be further extended to other preclinical cancer
models.
RESULTS AND DISCUSSION
Synthesis and Characterization of 198Au-Incorporated Au
Nanostructures. In this study, we employed the strategy
of directly incorporating the radionuclide 198Au into
the crystal lattice of nanostructures to compare the
tumor passive targeting efficiency and intratumoral
distribution of Au nanostructures with four different
shapes. As we recently demonstrated with Au
nanocages,11 the γ radiation from 198Au could be used
for quantitative analyses of biodistribution and tumor
targeting efficacy, whereas the visible light generated
from β emission could be employed for in vivo
Cerenkov imaging. Here we further extended this ap-
proach to other types of Au nanostructures including
nanospheres, nanodisks, and nanorods and then used
these nanostructures as probes to understand the
impacts of shape on their biodistribution, tumor tar-
geting capability, and intratumoral distribution. Since
the radionuclide is incorporated into the crystal lattice
of a nanostructure, rather than attached to the surface
through a molecular linker, we could accurately ana-
lyze the nanostructures in vivowithout worrying about
potential issues associated with the linker, including
in vivo instability and changes to surface characteristics
that will affect the biodistribution of nanostructures.6
The Au nanostructures were synthesized with a
similar size (the largest dimension for those with a
nonspherical shape) around 50 nm, which is known to
display a signiﬁcant EPR eﬀect for tumor targeting
(Supporting Information Table S1).17 Four distinct
shapes, including spherical,28 disk-like,29 rod-shaped,30
and cubic,6,31 were evaluated. Figure 1 shows TEM
images of these nanostructures in the nonradioactive
form. Figure S1 shows the LSPR spectra taken from
their aqueous suspensions. The nanospheres had an
LSPR peak at 532 nm, while the other three types of
nanostructures all showed LSPRpeaks in theNIR region
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due to their anisotropy in structure, rendering them
potential in vivo theranostic agents. Speciﬁcally, the
LSPR peaks of the nanodisks, nanorods, and nanocages
were located at 769, 817, and 778 nm, respectively.
To use the radioactive property for biodistribution
analysis, luminescence imaging, and tumor auto-
radiographic imaging, 198Au was directly incorporated
into the crystal lattice of the Au nanostructure simply
by mixing radioactive H198AuCl4 with nonradioactive
HAuCl4 prior to their use as the reagents for chemical
reduction or galvanic replacement. For each sample of
Au nanostructures, the speciﬁc radioactivity could be
tightly controlled by varying the ratio of H198AuCl4 to
HAuCl4 in themixture while keeping their total amount
and therefore the LSPR properties of the resultant
nanostructures unchanged.
Biodistribution of PEGylated, 198Au-Incorporated Au Nano-
structures. Once the198Au-incorporatedAunanostructures
with four distinct shapes had been prepared and sur-
face-functionalized with poly(ethylene glycol) (PEG,
MW ≈ 5000), they were injected intravenously via
the tail vein into mice bearing EMT6 tumors for a
quantitative analysis of biodistribution by tracing the
γ radiation from 198Au. Since the 198Au was incorpo-
rated into the lattice of each nanostructure, the 198Au
radiolabel showed good stability inmouse serumup to
a week as we have demonstrated in a previous study.11
By tracking the radiation emitted by 198Au, we could
accurately resolve the spatial distribution of the
198Au-incorporated nanostructures. Similar to the
biodistribution profiles previously reported for Au
nanostructures,3,6,32,33 all the samples of Au nano-
structures showed high hepatic and splenic accu-
mulation (Figures 2 and S2). However, for the Au
nanostructures with different shapes, they displayed
significant differences for the in vivo pharmacokinetic
profiles. Specifically, the PEGylated Au nanospheres
circulated in the bloodstream significantly longer than
the other three types of nanostructures, with 24.8%
injected dose per gram of tissue or blood (% ID/g)
circulating at 6 h and 10.4% ID/g remaining in the
blood at 24 h postinjection. The nanodisks showed
moderate blood circulation, with 16.5% ID/g remaining
in the blood at 1 h postinjection, 9.7% ID/g remaining
after 6 h, and 0.5% ID/g after 24 h. The nanorods had
the worst blood circulation compared with both nano-
spheres and nanodisks: 11.2% ID/g remained in the
blood after 1 h, which further decreased to 0.9% ID/g at
6 h postinjection. The poor performance of Au nano-
rods can likely be attributed to the low coverage
density of PEG chains on the surface due to slow
replacement of the cetyltrimethylammonium bromide
(CTAB) bilayer by PEG. Compared with the nanorods,
the nanocages showed much better blood circulation,
which hardly changed during the first 6 h (15.3 and
14.2% ID/g at 1 and 6 h, respectively). Although all
types of Au nanostructures showed significant accu-
mulation (20.7 to 43.9% ID/g, depending on the shape)
in the liver at 1 h postinjection, the nanospheres
showed the least clearance by the mononuclear
phagocytic system (MPS), in particular, Kupffer cells in
the liver. At 24 h, 34.9% ID/gof nanosphereswas located
in the liver compared to 55.0, 52.1, and 63.4% ID/g for
the nanodisks, nanorods, and nanocages, respectively.
Furthermore, a smaller portion of the nanospheres
accumulated in the spleen relative to other samples,
with 5.0% ID/g present at 24 h postinjection, compared
to >40% ID/g for nanostructures with the other three
shapes within the same time frame. Additional studies
were also performed at 24 h postinjection to determine
the clearance of these nanostructures by analyzing
the Au contents in urine and feces through the use of
inductively coupled plasma mass spectrometry. We did
not observe any significant clearance for the four types
of Au nanostructures used in the present work.
Due to their high blood retention and low clearance
by the liver and spleen, the PEGylated Au nanospheres
showed better accumulation in tumors than the nano-
structureswith other shapes, increasing from2.1% ID/gat
1 h to 11.5% ID/g at 6 h and up to 23.2% ID/g at 24 h. The
accumulation of nanodisks in tumors was observed to
surge up to 6 h, increasing from 1.5% ID/g at 1 h to 4.4%
ID/g at 6 h. Interestingly, the nanodisks remained in the
lungmore severely than any other shape, with 4.9% ID/g
remaining at 24 h postinjection, suggesting other poten-
tial applications for pulmonary imaging or therapy.
Due to the low blood circulation, the nanorods did
not eﬃciently accumulate in the tumors, with less than
2.0% ID/g accumulated even at 24 h postinjection. The
nanocages accumulated in tumors throughout the 24 h
period, increasing from 1.2% ID/g at 1 h to 4.7% ID/g at
6 h and ﬁnally 7.5% ID/g at 24 h postinjection.
Figure 1. TEM images of the four diﬀerent types of Au
nanostructures in the nonradioactive version: (a) nano-
spheres, (b) nanodisks, (c) nanorods, and (d) cubic nano-
cages. The scale bar applies to all images.
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In Vivo Luminescence Imaging. In addition to quantita-
tive analysis of biodistribution by following the
γ emission, in vivo luminescence imaging was also
performed on the mice bearing EMT6 tumors by
monitoring the Cerenkov radiationwith a conventional
optical in vivo imaging system (IVIS).11 Significantly,
luminescence in the visible region could be detected
with a low background from all the Au nanostructures
in vivo, which could be used to resolve their locations
through co-registration with the anatomical X-ray
images.As illustrated inFigure3, all the 198Au-incorporated
nanostructures showed accumulation in the tumors in the
optical images captured at 24 h postinjection. The
luminescence intensities from tumors in mice injected
with the nanospheres, nanodisks, and nanocages in-
creased throughout the 24 h period. The changes in
luminescence intensity over time generally matched
the kinetic data obtained for all the four samples
(Figure S3). These data are in agreement with the
time-dependent biodistribution shown in Figure 2.
In addition, luminescence was observed in areas cor-
responding to liver and spleen after the injection of all
the Au nanostructures. Much stronger luminescence
was recorded from the tumor region for both the
Figure 2. Biodistribution of the diﬀerent types of 198Au-incorporated Au nanostructures at (a) 1 h, (b) 6 h, and (c) 24 h
postinjection, together with the tumor uptake data (insets). See Figure S2 for the biodistribution data in terms of % ID/organ.
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nanospheres (Figure 3a, 4.7  104 counts) and nano-
disks (Figure 3b, 3.9  104 counts) relative to the
nanorods (Figure 3c, 2.6  104 counts) and nanocages
(Figure 3d, 2.8  104 counts) at 24 h postinjection,
which is different from the order observed for bio-
distribution. Since the Cerenkov luminescence pro-
duced from radioactive decay is expected to experi-
ence attenuation due to the absorption and scattering
by tissues before it reaches the detector, other factors
such as intratumoral distribution can have an impact
on its intensity. After the animal organs had been
harvested, the luminescence signals were mainly de-
tected from liver, spleen, and tumor for all the four
types of nanostructureswith intensities consistentwith
the data obtained in biodistribution studies (Figure S4).
Previously, we have examined the in vivo toxicity of Au
nanostructures with a dose of 400 μg/mouse via
histological analysis and did not observe any toxic
effect.34 In this study, with the administration of Au
nanostructures at a less amount, we did not observe
any adverse effect either.
Intratumoral Distribution of Nanostructures. In order to
better understand the shape dependence of intratu-
moral distribution for the Au nanostructures, the tu-
mors were excised from themice at 24 h postinjection,
microtomed into multiple slices of about 50 μm thick.
The cross sections of these slices were then subjected
to autoradiography imaging. Noticeable differences
were observed for the Au nanostructures with dif-
ferent shapes. Interestingly, signals associated with the
198Au-incorporated nanostructures were only detected
in the periphery of the tumors for both nanospheres
(Figure 4a) and nanodisks (Figure 4b), whereas signals
were detected throughout the tumor when the mice
were injected with either nanorods (Figure 4c) or
nanocages (Figure 4d). In addition, for the case of
nanorods or nanocages, the strongest signal was
located at the core of the tumor. This result offers
one explanation for the observation that tumors in the
mice injected with the nanospheres or nanodisks
showed stronger luminescence than the tumors in
mice injected with the nanorods or nanocages. We
believe that the Cerenkov radiation was attenuated
more significantly when originating from the core
rather than the surface of a tumor because the photons
had to travel through a thicker layer of tissue before it
was detected. Of course, other factors such as the level
Figure 3. Co-registered in vivo luminescence and X-ray images of the tumor-bearing mice at 1 h (left panel) and 24 h (right
panel) postinjection of thediﬀerent types of 198Au-incorporatednanostructures: (a) nanospheres, (b) nanodisks, (c) nanorods,
and (d) cubic nanocages.
Figure 4. Autoradiographic images of tumor slices at 24 h
postinjection of the diﬀerent types of 198Au-incorporated
Au nanostructures: (a) nanospheres, (b) nanodisks, (c) nano-
rods, and (d) cubic nanocages.
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of accumulation also played a role, as supported by the
nanospheres, which exhibited both the greatest% ID/g
accumulation in tumor and the strongest lumines-
cence intensity in the region of interest (ROI). More-
over, it should be pointed out that the actual size of
nanoparticles can also affect the intratumoral distribu-
tion profile.35 A further study comparing the intratu-
moral distributions of nanoparticles with different sizes
will lead to the identification of nanostructure with
optimal size and shapes for cancer imaging and
therapy.
The accumulation of nanostructures in tumors can
be explained by the EPR eﬀect, a well-established
phenomenon that plays an important role in both
passive and active targeting. This phenomenon, how-
ever, only occurs in vascularized tumors, and the
eﬃcacy is closely related to the angiogenesis process
and tumor vasculature.1416,36,37 To validate the invol-
vement of the EPR eﬀect in our system, we used PA
imaging to characterize the vasculature in the EMT6
tumor. Figure 5a shows a coronal (top view) maximum
amplitude projection (MAP) image, clearly revealing
the vasculatures inside the tumor (indicated by the
dashed circle) and surrounding tissues. The sagittal
(side view) MAP image in Figure 5b shows a well-
resolved vasculature to a depth of approximately
2.1 mm. The tumor blood volume quantiﬁed by PA
imaging was 2.3( 0.2 times greater than other tissues,
consistent with the fast-growing nature of the EMT6
tumor model.6 The vasculature present in the EMT6
tumor provides an avenue for the nanostructures to
transport into the tumor. The vascularity was further
characterized by histological staining (Figure S5) and
PET imaging with 64Cu(II) diacetylbis(N4-methylthio-
semicarbazone) (64Cu-ATSM),38 which was supposed
to be localized in the hypoxic regions away from the
vasculature. As shown in Figures 6 and S6, the uptake
of 64Cu-ATSMwas relatively low. Speciﬁcally, the tumor
was characterized by a standardized uptake value
(SUV) of 0.4 ( 0.1, tumor-to-muscle ratio of 2.1 ( 0.4,
and accumulation of 2.0 ( 0.6% ID/g for 64Cu-ATSM.
The accumulationwasmuch lower than the data (4.2(
1.0% ID/g) previously reported for the hypoxic EMT6
tumor at a later stage of development,39 conﬁrming
the well-oxygenated tumor environment and active
angiogenesis process during the study period, as
shown in Figure 5b.
In general, most solid tumors have a heterogeneous
pattern of intratumoral blood vessels. As shown in
Figure S5, the vasculature in the EMT6 tumor was
largely heterogeneously distributed, with vessel den-
sity varying greatly throughout the tumor. We also
observed a heterogeneous microenvironment consist-
ing of blood vessels, individual red blood cells asso-
ciated with the leaky vessels, and necrotic areas
containing inﬂammatory cells. Interestingly, high me-
tabolism in the tumor was conﬁrmed by PET imaging
with 18F-ﬂourinated deoxyglucose (18F-FDG) (Figure 6).40
Signiﬁcant tumor uptake of 18F-FDG was observed,
with SUV of 1.5 ( 0.3, accumulation of 8.0 ( 1.2% ID/g,
and tumor-to-muscle ratio of 5.8 ( 1.4. The 18F-FDG
uptake was relatively homogeneous throughout the
tumor volume, suggesting a general glycolytic pheno-
type throughout both aerobic and anaerobic micro-
environments, a common characteristic of many types
of cancers.
The data from PA imaging, histology staining, and
PET imaging all showed the hallmarks expected for the
tumor model, including the presence of intratumoral
vasculature, heterogeneous microenvironments, and
highmetabolism of glucose. We can take advantage of
these features to deliver nanostructures into tumors
for diagnosis and photothermal therapy. While the
vasculature serves as an entryway for nanostructures
to enter the tumor, it is the convective ﬂow that
determines intratumoral distribution of nanostructures.
Figure 5. Photoacoustic microscopy images of the EMT6
tumor in a mouse: (a) coronal MAP image viewed from the
top and (b) sagittal MAP image viewed from the side.
Figure 6. (Left) Co-registered 18F-FDG PET/CT images of a
BALB/c mouse bearing a EMT6 tumor. (Right) Quantitative
comparisons of standardized uptake values, % ID/g, and
tumor/muscle ratios for the 18F-FDGand 64Cu-ATSM tracers.
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The nanostructures can accumulate in a tumor by
leaking out through the pores in the vascular walls
due to the EPR eﬀect. Once outside the vasculature,
however, the transport of nanostructures is controlled
by diﬀusion through the hypoxic microenvironments.
To be distributed throughout the EMT6 tumor, the
nanostructuresmust be able to ﬂow through the tumor
microvasculature, leak out through pores in the vas-
cular walls, and then diﬀuse through distinct micro-
environments containing necrotic, avascular volumes.
It has been observed that nanostructures with smaller
sizes were able to diﬀuse deeper into tumors com-
pared to their larger counterparts,41 and that the
transport of nanorods through porous media was
mainly determined by the smaller dimension.27 In this
study, all the four colloidal samples of Au nanostruc-
tures showed good stability when incubated with 10%
fetal bovine serum in phosphate buﬀer saline at 37 C
for up to 24 h (Figure S7), excluding the possible eﬀect
of particle aggregation on the EPR eﬀect. Since the Au
nanorods had two of their dimensions less than 15 nm,
they should have a better chance to leak out through
the small pores in the microvasculature of a tumor and
penetrate into the tumor volume, as evidenced by the
autoradiography image in Figure 4c. Other factors such
as the tumbling motion of a nanorod under ﬂow and
the diﬀusionmotion outside the vasculature could also
aﬀect its ability to penetrate through the tumor.42
The shape of a particle can aﬀect its properties such
as the friction coeﬃcient,42 resistance, and buoyancy.43
For vasculature-based passive targeting, the convec-
tive ﬂow inside the vessels, which also determines the
intratumoral distribution of nanoparticles, is largely
determined by the pressure diﬀerence between the
vasculature and the interstitial space of a tumor.41
Because the nanocage has a hollow core and six ﬂat
faces, these factors may signiﬁcantly increase its con-
vective and diﬀusive properties in the tumor tissue
compared to the spherical counterparts. Additionally,
the hollow core gives the nanocage a lower density,
which can aﬀect their resistance and increase buoy-
ancy during diﬀusive transport in vivo. As revealed by
the autoradiography image in Figure 4d, these eﬀects
allow the nanocage to ﬂow through tumor micro-
vasculature, leak out through pores, and diﬀuse
through interstitial tumor space to reach micro-
environments inside the entire tumor.
CONCLUSION
In summary, we have demonstrated the synthesis of
radioactive Au nanostructures with a similar size but
four diﬀerent shapes by directly incorporating 198Au
into their crystal lattices. The radiolabeling integrity
and stability associated with these nanostructures
have enabled us to quantitatively analyze their biodis-
tribution, tumor uptake, and intratumoral distribution
using a murine EMT6 breast cancer model. Speciﬁcally,
the biodistribution could be quantiﬁed by measuring
the γ radiation from 198Au, whereas both tumor uptake
and intratumoral distribution could be measured by
detecting the β emission for Cerenkov radiation and
autoradiography. Of the four shapes, the 198Au-incor-
porated nanospheres showed the best blood circula-
tion, the lowest clearance by the reticuloendothelial
system, and the highest overall tumor uptake relative
to nanodisks, nanorods, and nanocages. Interestingly,
nanorods and nanocages could reach the cores of the
tumors, whereas nanospheres and nanodisks were
only observed on the surfaces of the tumors, suggest-
ing the unique positions of Au nanorods and nano-
cages for photothermal cancer treatment.34 Future
studies need to focus on further improving the blood
circulation half-life and pharmacokinetics of these Au
nanostructures to reduce uptake by liver and spleen
and minimize radiation burden, test these 198Au nano-
structures in other tumor models, and add molecular
targeting ligands to their surfaces to increase their
tumor uptake for better use of the therapeutic cap-
ability provided by the β emission and photothermal
conversion.
MATERIALS AND METHODS
Chemicals and Reagents. Poly(ethylene glycol)monomethyl
ether thiol (Mw ≈ 5000 Da) was purchased from Laysan Bio
(Arab, AL). All other chemicals or reagents, including sodium
borohydride (NaBH4), CTAB, chloroauric acid (HAuCl4), ascorbic
acid, sodium citrate, silver nitrate (AgNO3), concentrated hydro-
chloric acid (HCl, 37%), and nitric acid (HNO3) were obtained
from Sigma-Aldrich (St. Louis, MO). All chemicals were used as
received.
Preparation of Radioactive H198AuCl4. Proper radiation safety
training and personal protection equipment are required be-
cause 198Au is a strong β emitter (Emax = 0.96 MeV, 99%
abundance). The 198Au (specific activity = 3.7 GBq/mg) was
produced at the University of Missouri using the MURR irradia-
tion facility. Briefly, 530 mg of Au foil was irradiated at a flux
of 8  1013 n/cm2/s. After irradiation, the radioactive foil
was dissolved with 0.4 mL of freshly prepared aqua regia
(HCl/HNO3 = 3/1, v/v) under heating at 90 C for 5 min. The
solution was then dried by heating at 100 C, reconstituted in
0.4 mL of 0.05 M HCl twice, and finally reconstituted in 0.1 M
HCl for shipping. Upon receiving, the sample was dried by
heating to 130 C and reconstituted in ultrapure water. This
procedure was repeated three times to remove the acids and
nitrogen oxide byproducts. To incorporate 198Au into the
lattices of the Au nanostructures, the radioactive H198AuCl4
was mixed with nonradioactive HAuCl4 prior to their use in a
synthesis.
Preparation of 198Au-Incorporated Au Nanodisks. The radioactive
nanodisks were prepared by etching away the corners of Au
triangular nanodisks, which were synthesized by following a
previously reported method with the use of 107 MBq of
H198AuCl4.
29 After the 198Au-incorporated triangular nanodisks
were purified by centrifugation, aqueous HAuCl4 solution
(10 mM) in CTAB (100 nM) was added slowly (13 μL for each
time) into 1 mL of the triangular nanodisks to generate round
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nanodisks. The reactionwas stopped by centrifugation once the
LSPR peak had reached 770 nm.
Preparation of 198Au-Incorporated Au Nanocages. The radioactive
nanocages were prepared via the galvanic replacement reac-
tion between Ag nanocubes and a mixture of H198AuCl4 and
HAuCl4.
31 An aqueous suspension of Ag nanocubes (48 nm in
edge length) were prepared, and then titrated with an aqueous
solution containing H198AuCl4 (81 MBq) and HAuCl4 (0.75 mM)
dropwise (30mL/h). The reactionwas stopped by centrifugation
when the LSPR peak had reached 780 nm.
Preparation of 198Au-Incorporated Au Nanospheres. The radioactive
nanospheres were prepared via seed-mediated growth by
using ascorbic acid as a reducing agent and sodium citrate as
a colloidal stabilizer.28 The synthesis involved the use of 59MBq
of H198AuCl4 and 30 nm Au nanospheres as the seeds. The
reaction was stopped by centrifugation once the LSPR peak had
reached 530 nm.
Preparation of 198Au-Incorporated Au Nanorods. The radioactive
nanorods were prepared using a seed-mediated method that
involved the addition of a suspension of Au spherical seeds to a
growth solution in the presence of CTAB as a capping agent.30
First, 250 μL of an aqueous HAuCl4 solution (10 mM) was added
to 7.5 mL of a 0.1 M CTAB solution in a 20 mL glass vial. Then,
0.6 mL of an aqueous NaBH4 solution (10 mM, ice-cold) was
added in one shot under vigorous stirring. The as-obtained
nanospheres were used as the seeds for the growth of Au
nanorods. In a typical process, 4.75 mL of 0.1 M CTAB, 0.2 mL of
10 mM HAuCl4 containing 7.8 MBq of H
198AuCl4, and 30 μL of
10 mM AgNO3 were added stepwise to a glass vial, followed by
gentle mixing. The solution at this stage appeared bright
brown-yellow in color. Then 32 μL of 0.1 M ascorbic acid was
added, and the solution became colorless upon mixing. Finally,
20 μL of the seed solution was added, and the reaction mixture
was gently mixed for 10 s and then left undisturbed for 3 h. The
specific activities of the four samples of 198Au-incorporated
nanostructures are listed in Table S1.
Conjugation of PEG with Au Nanostructures. Four milliliters of the
Au nanostructures in ultrapurified H2O (0.050.2 mg/mL in Au
content as determined by ICP-MS) was mixed with 2.0 mg of
mPEG-SH and incubated overnight at room temperature. The
excess mPEG-SH was removed by centrifugation, and the solids
were washed three times with ultrapurified H2O to obtain the
PEGylated Au nanostructures.
Electron Microscopy. To determine morphology, the nano-
particles were deposited on TEM grids and examined using a
Tecnai G2 Spirit transmission electron microscope (TEM) oper-
ated at 120 kV (FEI, Hillsboro, OR).
Tumor Mouse Model. All animal studies were performed in
compliance with guidelines set forth by the NIH Office of
Laboratory Animal Welfare and approved by the Washington
University Animal Studies Committee. The EMT6 murine mam-
mary carcinoma cells (ATCC, Manassas, VA) were cultured in
Waymouth's MB 752/1 medium with 85% 2 mM L-glutamine
and 15% fetal bovine serum at 37 C with 5% CO2. EMT6 cells
(2 105) in 100μL salinewere injected into the right flank, back, or
hind flank of 7 week old female BALB/c mice weighing 1520 g.
Tumors were allowed to grow for 810 days, reaching an
average size of 100 mm3, before further studies were
performed.
In Vivo Biodistribution. EMT6 tumor-bearing BALB/c mice were
anesthetized with inhaled isoflurane before 185370 kBq of
198Au-incorporated nanospheres (314 kBq, 5.27 μg/mouse),
nanodisks (185 kBq, 27.8 μg/mouse), nanorods (326 kBq,
4.22 μg/mouse), or nanocages (225 kBq, 17.9 μg/mouse)
(suspended in 100 μL saline) was injected via the tail vein. After
re-anesthetization, the mice were euthanized by cervical dis-
location 1, 6, or 24 h after injection (n=4 animals per time point).
Organs of interest were collected, weighed, and counted in a
well Beckman 8000 gamma counter (Beckman, Brea, CA).
Standards were prepared andmeasured alongwith the samples
to calculate percentage of the injected dose per gram of tissue
(% ID/g).
In Vivo Luminescence Imaging. EMT6 tumor-bearing BALB/c
mice (n = 2) were anesthetized with isoflurane before
1.793.83 MBq of 198Au-incorporated nanospheres (3.83 MBq,
64.7 μg/mouse), nanodisks (2.94 MBq, 442 μg/mouse), nano-
rods (1.79 MBq, 23.1 μg/mouse), or nanocages (2.48 MBq,
197 μg/mouse) (suspended in 100 μL saline) was injected via
the tail vein. In vivo radioactive optical imaging was performed
with an IVIS 100 Spectrum system (PerkinElmer, Waltham, MA).
Themouse was placed in a light-tight chamber under isoflurane
anesthesia, and luminescent images were acquired over 5 min
at 1 and 24 h postinjection. Images were analyzed using Living
Image 3.0 software (Caliper Life Sciences, Hopkinton, MA). The
optical signal was normalized to p/s/cm2/sr, and the emission
intensity was normalized to the radioactivity injected.
Autoradiographic Imaging. Tumors were excised from the mice
after Cerenkov imaging and fixed in 4% paraformaldehyde.
The tumors were frozen in Optimal Cutting Temperature com-
pound and then cut with a Vibratome 8850 whole body cryo-
microtome (SIMS Co., Ltd., Tokyo, Japan) into 820 slices, with
each slice being 50 μm thick. The slices were placed on glass
slides for 2D autoradiography using an Instant Imager Electronic
Autoradiography system (Packard, Meriden, CT). Images were
acquiredandanalyzedwith Imager software (Packard,Meriden,CT).
In Vivo PA Imaging. EMT6 tumor-bearing BALB/c mice (n = 6)
were imaged 810 days after injection with EMT6 cells as
described above. The PA imaging system was an updated
version of what was used in previous publications,44,45 and it
relies on the collection of photoacoustic signals generated from
the absorbed laser irradiation. The light source was a tunable
dye laser (Cobra, Sirah) pumped by a Nd:YLF laser (INNOSLAB,
EdgeWave), providing 7 ns laser pulse width with a pulse
repetition rate up to 5 kHz. The output light was coupled into
a multimode fiber (M30L02, Thorlabs), passed through a conical
lens, and then weakly focused by an optical condenser into the
sample. The generated ultrasound signal was collected by the
acoustic lens, which was in confocal arrangement with the
focused laser beam, and received by a 50 MHz ultrasound
transducer (V214-BB-RM, Olympus NDT). For each laser shot, a
1D depth-resolved image (A-line) was acquired without me-
chanical scanning. By raster-scanning along the transverse
plane, a 2D image was acquired, which could be expanded to
three dimensions by collecting 2D images at multiple focal
planes throughout the tumor volume. Volumetric images can
be viewed through either MAP or direct 3D rendering. MAP was
performed by projecting the maximum signal amplitude along
the z axis (depth) or other axes. A field of view of 12 mm  10
mm can be acquired within about 1 min. The lateral and axial
resolution of the system were 45 and 15 μm, respectively. The
pulse energy at the skin surface was about 5 mJ/cm2, which is
well below the standard limit regulated by the American
National Standards Institute standards (ANSI Z136.1).
In Vivo PET Imaging. To characterize tumor glucose uptake and
hypoxia, PET imagingwasperformedwith 18F-FDGand 64Cu-ATSM,
respectively. PET and the corresponding CT images were acquired
in either an Inveon microPET/CT scanner (Siemens, Munich,
Germany) or a Focus 220 PET scanner (Concorde Microsystems,
Knoxville, TN). To measure glucose uptake, EMT6 tumor-bearing
BALB/c mice were fasted for 4 h and anesthetized with isoflurane
before 11.1 MBq of 18F-FDG acquired from the Washington Uni-
versity cyclotron facility was injected via the tail vein. Dynamic
scans were acquired every 5 min until 1 h postinjection. Images
were analyzed with Inveon software (Siemens, Munich, Germany).
For hypoxia studies, ATSM was ﬁrst labeled with 64Cu
acquired from the Washington University cyclotron facility
through a reported protocol.38 Brieﬂy, 117 MBq of 64Cu was
dissolved in 100 μL of water. An aliquot of 5 mL of ATSM
reconstitution solution (10% propylene glycol, 1.25% sodium
acetate in sterile water) was mixed with 7.5 μg of lyophilized
ATSM ligand and vortexed vigorously for 1 min. Then 1 mL of
the ATSM stock solution was added to the 64Cu solution and
vortexed vigorously for 30 s. Radiochemical purity of the 64Cu-
ATSM was tested with an Oasis cartridge (Waters, Milford, MA)
and conﬁrmed to be >95% before the sample was diluted with
2 mL saline. EMT6 tumor-bearing BALB/c mice were anesthe-
tized with isoﬂurane, and 100 μL of saline containing 3 MBq of
64Cu-ATSM was injected via the tail vein. Dynamic scans were
acquired every 5 min until 1 h postinjection. Images were
analyzed with Inveon software (Siemens, Munich, Germany).
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